Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) will be posting its quarterly earnings results after the market closes on Thursday, November 14th. Analysts expect Aurinia Pharmaceuticals to post earnings of C($0.26) per share for the quarter.
TSE AUP opened at C$6.62 on Wednesday. Aurinia Pharmaceuticals has a one year low of C$4.70 and a one year high of C$10.47. The company has a 50-day simple moving average of C$6.60 and a 200-day simple moving average of C$7.85. The company has a debt-to-equity ratio of 0.33, a quick ratio of 18.05 and a current ratio of 18.98. The firm has a market capitalization of $649.80 million and a PE ratio of -9.50.
Several research analysts have recently commented on the stock. Bloom Burton reaffirmed a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aurinia Pharmaceuticals in a report on Thursday, October 17th.
In other Aurinia Pharmaceuticals news, Senior Officer Bradley Dickerson purchased 5,000 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was acquired at an average cost of C$5.11 per share, with a total value of C$25,542.00. Following the acquisition, the insider now owns 15,000 shares of the company’s stock, valued at approximately C$76,626. Insiders bought a total of 9,550 shares of company stock valued at $53,567 over the last ninety days.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Read More: What is a dead cat bounce?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.